Received further clarification on Potential new studies financed :
Use of FundsThe Company will use the proceeds received from the Placement to fund an expanded clinical program including the following:New Phase III Registration Trial–metastatic breast cancer (based on AIPAC)New Phase IITrial–triple combination therapy with efti + anti-PD-1 therapy + chemotherapy (expected indication: NSCLC)Other Trials – two new investigator-initiated trials (IITs) with up to 40 patients eachManufacturing & validation–commence process characterisation and process validation for efti commercial manufacturing (2,000 litre scale)Regulatory–ongoing interactions with the FDA and EMAAutoimmune Program–IND package for IMP761Strengthen–the team and research projects
Received further clarification on Potential new studies financed...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |